EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CMV IgG in the blood is not associated with hepatitis but correlates with poor outcomes in immunotherapy treated melanoma patients

Sophia B Strobel, Devayani Machiraju, Melanie Wiecken, Jasmin Richter, Julian A F Klein, Annemarie Berger, Jessica C Hassel

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-024-03859-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Sophia B Strobel und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and National Center for Tumor Diseases (NCT), Medical Faculty Heidelberg, NCT Heidelberg, a partnership between DKFZ and Un…. Hauptthemen laut MEDLINE: Melanoma, Immunoglobulin G, Cytomegalovirus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medizinische Fakultät Heidelberg der Universität Heidelberg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cytomegalovirus (CMV) infection or reactivation in immune-compromised individuals can lead to a wide range of severe complications including hepatitis. However, its relation with immune checkpoint inhibitors (ICIs) induced hepatitis (ICI-hepatitis) and tumor responses in advanced melanoma patients remains unclear. Hundred and ninety metastatic cutaneous melanoma patients (mCM) who received ICI treatment, with CMV IgG or IgM information available at baseline, were included in the study (Cohort 1). Clinical characteristics and immune cell count in the blood were retrieved from medical records. In addition, anti-CMV IgG and IgM were measured in pre and on-treatment serum samples from 49 advanced skin cancer patients using ELISA (Cohort 2). In the event of a positive anti-CMV IgM, further analysis with PCR was performed. Univariate and multivariate analysis was used to assess the relationship between CMV IgG or IgM and ICI-hepatitis tumor outcomes. Twenty-one patients (11%) developed hepatitis during ICI treatment (Cohort 1). ICI-hepatitis was significantly associated with disease control rate (DCR; p = 0.017) and longer progression-free survival (PFS; p = 0.008) in mCM patients. Detection of CMV IgG or IgM antibodies were not associated with ICI-hepatitis ( p > 0.05). However, increased CMV IgG values at baseline correlated with disease progression ( p = 0.047) and shorter PFS ( p = 0.081). In addition, increased CMV IgG values were associated with reduced levels of monocytes ( p = 0.005), eosinophils ( p = 0.062), and neutrophils ( p = 0.065) in the blood. In summary, anti-CMV IgG or IgM in the blood may not be associated with ICI-hepatitis, but high anti-CMV IgG at baseline indicates poor outcomes in ICI-treated mCM patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaImmunoglobulin GCytomegalovirusHumansMaleFemaleMiddle AgedAgedAdultHepatitisImmune Checkpoint InhibitorsImmunotherapyCytomegalovirus InfectionsSkin NeoplasmsAged, 80 and overPrognosisAntibodies, Viral

Stichwörter der Autor:innen

CMVHepatitisIgGIgMImmunotherapyMelanomaPeripheral Immune cellsSurvival

Substanzen

Immunoglobulin GImmune Checkpoint InhibitorsAntibodies, Viral

Autor:innen und Institutionen

  • Department of Dermatology and National Center for Tumor Diseases (NCT), Medical Faculty Heidelberg, NCT Heidelberg, a partnership between DKFZ and University Hospital Heidelberg, Heidelberg University, Heidelberg, Germa…
  • Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.
  • Department of Dermatology, Venereology and Allergology, University Medical Center, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
  • Department of Virology, Centre for Infectious Diseases, University Hospital Heidelberg, Heidelberg, Germany.
  • University Hospital, Institute for Medical Virology, Goethe University Frankfurt, Frankfurt, Germany.

Förderung

  • Medizinische Fakultät Heidelberg der Universität Heidelberg

Zitieren

APA

Strobel, S. B., Machiraju, D., Wiecken, M., Richter, J., Klein, J. A. F., Berger, A., & Hassel, J. C. (2025). CMV IgG in the blood is not associated with hepatitis but correlates with poor outcomes in immunotherapy treated melanoma patients. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03859-3

Vancouver

Strobel SB, Machiraju D, Wiecken M, Richter J, Klein JAF, Berger A, et al. CMV IgG in the blood is not associated with hepatitis but correlates with poor outcomes in immunotherapy treated melanoma patients. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-024-03859-3

BibTeX
@article{Strobel2025,
  author = {Strobel, Sophia B and Machiraju, Devayani and Wiecken, Melanie and Richter, Jasmin and Klein, Julian A F and Berger, Annemarie and Hassel, Jessica C},
  title = {CMV IgG in the blood is not associated with hepatitis but correlates with poor outcomes in immunotherapy treated melanoma patients},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-024-03859-3}
}
Kostenlos starten →